Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery.
basal-like subtype
breast cancer
comedo-like necrosis
deep venous thrombosis
pulmonary embolism
venous thromboembolism
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Feb 2022
16 Feb 2022
Historique:
received:
03
01
2022
revised:
12
02
2022
accepted:
13
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Albeit it does not have the highest venous thromboembolism (VTE) incidence compared to other neoplasms, breast cancer contributes to many VTE events because it is the most diagnosed tumor in women. We aim to analyze the occurrence and timing of VTE during the follow-up of patients who underwent breast surgery, the possible correlated factors, and the overall survival. This retrospective study included all female patients diagnosed with mammary pathology and surgically treated in our clinic between January 2002 and January 2012. Of 5039 women who underwent breast surgery, 1056 were found to have no evidence of malignancy, whereas 3983 were diagnosed with breast cancer. VTE rate resulted significantly higher in patients with invasive breast cancer than in women with benign breast disease or carcinoma in situ. Invasive cancers other than lobular or ductal were associated with a higher VTE rate. In addition, chronic hypertension, high BMI, cancer type, and evidence of metastasis turned out to be the most significant risk factors for VTE in women who underwent breast surgery. Moreover, VTE occurrence significantly impacted survival in invasive breast cancer patients. Compared to women with benign mammary pathology, VTE prevalence in women with breast cancer is significantly higher. The knowledge about the risk factors of VTE could be helpful as prognostic information, but also to eventually target preventive treatment strategies for VTE, as far as the co-existence of invasive breast cancer and VTE has a significantly negative impact on survival.
Identifiants
pubmed: 35205736
pii: cancers14040988
doi: 10.3390/cancers14040988
pmc: PMC8870485
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Intern Med J. 2012 Jan;42(1):71-4
pubmed: 21118408
Thromb Res. 2012 Jul;130(1):27-31
pubmed: 22154240
Ann Plast Surg. 2018 Feb;80(2):188-192
pubmed: 29095189
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Intern Med. 2014;53(5):413-9
pubmed: 24583428
TH Open. 2018 Apr 19;2(2):e158-e166
pubmed: 31249939
BMC Cancer. 2017 Nov 10;17(1):747
pubmed: 29126386
Breast. 2022 Feb;61:123-128
pubmed: 34995921
Am J Surg. 2016 Dec;212(6):1162-1166
pubmed: 27773376
Am Heart J. 1996 Oct;132(4):850-5
pubmed: 8831376
Clin Transl Oncol. 2020 Jun;22(6):870-877
pubmed: 31473984
Micron. 2016 Nov;90:59-63
pubmed: 27595902
Surg Today. 2013 Jan;43(1):100-2
pubmed: 22618999
Mol Pharm. 2017 Feb 6;14(2):513-522
pubmed: 28026951
Clin Cancer Res. 2016 Nov 1;22(21):5249-5255
pubmed: 27803117
J Clin Med. 2021 Nov 28;10(23):
pubmed: 34884304
Circulation. 2003 Jun 17;107(23 Suppl 1):I22-30
pubmed: 12814982
Ger Med Sci. 2013;11:Doc05
pubmed: 23423877
Biomed Res Int. 2014;2014:250727
pubmed: 24877073
Oncol Rep. 2014 Apr;31(4):1539-46
pubmed: 24534891
Int J Biol Macromol. 2018 Jun;112:343-355
pubmed: 29409771
Springerplus. 2015 Nov 10;4:688
pubmed: 26576331
Thromb Res. 2012 Oct;130 Suppl 1:S66-70
pubmed: 23026668
Thromb Haemost. 2015 Mar;113(3):593-8
pubmed: 25373787
Neth J Med. 2014 Jan;72(1):28-31
pubmed: 24457436
Thromb Res. 2019 May;177:51-58
pubmed: 30851629
Sci Rep. 2016 Jan 22;6:19603
pubmed: 26797411
Cancer. 2017 Feb 1;123(3):468-475
pubmed: 27727456
Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):329-34
pubmed: 11834537
BMJ Open. 2014 Jun 05;4(6):e005082
pubmed: 24902734
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
World J Surg. 2014 Sep;38(9):2279-87
pubmed: 24819382
Haematologica. 2020 Jun;105(6):1704-1711
pubmed: 31558668
Eur J Med Res. 2016 Mar 22;21:13
pubmed: 27004410
Microsc Microanal. 2016 Jun;22(3):630-9
pubmed: 27329313
Br J Haematol. 2018 Nov;183(3):346-363
pubmed: 30334572
Vascul Pharmacol. 2022 Feb;142:106931
pubmed: 34763100
BMJ. 2010 Mar 12;340:b5087
pubmed: 20228141
Br J Clin Pharmacol. 2021 Feb;87(2):237-255
pubmed: 32501544
Breast Cancer Res Treat. 2002 Jun;73(3):275-7
pubmed: 12160333
J Thromb Haemost. 2011 Feb;9(2):237-49
pubmed: 21040448
Clin Breast Cancer. 2014 Aug;14(4):235-40
pubmed: 24703317
J Thromb Haemost. 2017 Sep;15(9):1757-1763
pubmed: 28639418
Asia Pac J Clin Oncol. 2012 Sep;8(3):e12-6
pubmed: 22897494
Lancet Oncol. 2002 Jul;3(7):425-30
pubmed: 12142172
Breast. 2013 Aug;22(4):444-8
pubmed: 23692931
J Breast Cancer. 2012 Jun;15(2):148-56
pubmed: 22807931
Blood Adv. 2019 Oct 22;3(20):3080-3091
pubmed: 31648335
Blood. 2016 Feb 18;127(7):849-57; quiz 953
pubmed: 26574606
J Thromb Haemost. 2015 Mar;13(3):390-7
pubmed: 25529107
Breast Cancer. 2015 Jul;22(4):350-5
pubmed: 23832256
TH Open. 2021 Feb 10;5(1):e56-e65
pubmed: 33585786
Blood. 2014 Jan 9;123(2):249-60
pubmed: 24258815
Blood Coagul Fibrinolysis. 2021 Sep 1;32(6):373-381
pubmed: 33973894
J Thromb Haemost. 2020 Sep;18(9):2220-2231
pubmed: 32397009
Platelets. 2016;27(1):80-5
pubmed: 25970326
Breast Cancer (Dove Med Press). 2014 Feb 17;6:29-36
pubmed: 24648767
Medicine (Baltimore). 2019 Jan;98(1):e13831
pubmed: 30608397